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Introduction
The insulin- like growth factors, IGF- I and IGF- II, circulate 
in high concentrations, but at the cellular level, only a 
small fraction is able to stimulate the IGF- I receptor 
(IGF- IR), the primary target of the IGFs. This is due to 
the presence of six high- affinity binding proteins (IGFBPs), 
which are present in molar excess of the IGFs and fur-
thermore bind the IGFs with an affinity that exceeds that 
of the IGF- IR [1].
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Abstract
Measurement of circulating insulin- like growth factors (IGFs), in particular 
IGF- binding protein (IGFBP)- 2, at the time of diagnosis, is independently prog-
nostic in many cancers, but its clinical performance against other routinely 
determined prognosticators has not been examined. We measured IGF- I, IGF- II, 
pro- IGF- II, IGF bioactivity, IGFBP- 2, - 3, and pregnancy- associated plasma protein 
A (PAPP- A), an IGFBP regulator, in baseline samples of 301 women with breast 
cancer treated on four protocols (Odense, Denmark: 1993–1998). We evaluated 
performance characteristics (expressed as area under the curve, AUC) using 
Cox regression models to derive hazard ratios (HR) with 95% confidence in-
tervals (CIs) for 10- year recurrence- free survival (RFS) and overall survival (OS), 
and compared those against the clinically used Nottingham Prognostic Index 
(NPI). We measured the same biomarkers in 531 noncancer individuals to as-
sess multidimensional relationships (MDR), and evaluated additional prognostic 
models using survival artificial neural network (SANN) and survival support 
vector machines (SSVM), as these enhance capture of MDRs. For RFS, increas-
ing concentrations of circulating IGFBP- 2 and PAPP- A were independently 
prognostic [HRbiomarker doubling: 1.474 (95% CIs: 1.160, 1.875, P = 0.002) and 1.952 
(95% CIs: 1.364, 2.792, P < 0.001), respectively]. The AUCRFS for NPI was 0.626 
(Cox model), improving to 0.694 (P = 0.012) with the addition of IGFBP- 2 
plus PAPP- A. Derived AUCRFS using SANN and SSVM did not perform supe-
riorly. Similar patterns were observed for OS. These findings illustrate an im-
portant principle in biomarker qualification—measured circulating biomarkers 
may demonstrate independent prognostication, but this does not necessarily 
translate into substantial improvement in clinical performance.
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To activate the IGF- IR, the IGFs need to dissociate 
from the IGFBPs. This process is enhanced by IGFBP 
proteases, which cleave the IGFBPs and thereby reduce 
their ligand affinity markedly. PAPP- A is a metallopro-
teinase that cleaves a subset of IGFBPs, and thus functions 
as a growth- promoting enzyme, releasing bioactive IGF 
in close proximity to the IGF- IR [2]. PAPP- A is overex-
pressed in several tumor types, including breast cancer 
[3], but the prognostic significance of circulating PAPP- A 
remains uncertain.
There are established multidimensional relationships 
between the members of the IGF system. For example, 
in serum,  free IGF- I is positively correlated with its total 
circulating concentration; IGF- I and IGF- II are positively 
correlated with IGFBP- 3, which is the major IGF- carrier 
[1]; mean levels of IGF- I and IGF- II decrease with age, 
whereas mean IGFBP- 2 levels increase with age [4]; and 
IGF- I has a nonlinear inverted “U” shaped relationship 
with BMI [5, 6].
Insulin- like growth factor ligands have well- established 
tumor developing properties at a cellular level [7] and 
in the circulation, the concentration of IGF- I, and to a 
lesser extent that of IGFBP- 3, are associated with subse-
quent risk of developing prostate, pre- and postmenopausal 
breast cancer and colorectal cancer [8]. However, the role 
of circulating IGF- related peptides in patients after cancer 
diagnosis—for example as prognosticators—is unclear. 
Previous studies report that serum IGFBP- 2 concentrations 
are elevated in a stage- dependent manner in patients with 
numerous malignancies, including colorectal [9], prostate 
[10], ovarian [11], and lung [12] cancers, and might be 
prognostic, while serum IGFBP- 3 is implicated as prog-
nostic in patients with metastatic colorectal cancer under-
going chemotherapy [13].
The present authors previously compared a cohort of 
patients with early- stage breast cancer treated at the 
Odense University Hospital, Denmark, with matched 
controls [14], and showed that serum levels of free IGF- I 
and free IGF- II were elevated, whereas the respective total 
IGF levels were lower in patients with cancer than in 
controls. The findings from this small- scale, cross- sectional 
study (43 cancers; 38 controls) suggested that considera-
tion of multidimensional relationship (MDR) of the IGF 
system might yield additional insight compared with single 
components alone, as free IGF levels depend on total 
IGF and IGFBP concentrations as well as IGFBP- protease 
activity [1, 2].
We have previously capitalized on the modeling of 
multidimensional relationships of the IGF system using 
machine- driven approaches, such as artificial neural net-
works (ANN) [15], and demonstrated considerable 
improvements (over and above conventional regression 
models) in performance characteristics (and thus, potential 
clinical utility) after measuring multiple IGF- related bio-
markers in the detection of colorectal cancer.
Here, we extended the earlier report from the breast 
cancer cohort treated at Odense University Hospital; meas-
ured a panel of seven IGF- related circulating biomarkers; 
performed prognostic modeling against long- term survival; 
and then evaluated performance characteristics against the 
clinically used prognostic model, namely the Nottingham 
Prognostic Index (NPI). In addition to Cox regression 
models, we evaluated prognostic models using survival 
ANNs (SANNs) and survival support vector machines 
(SSVMs), as these enhance capture of multidimensional 
relationships.
Methods
Study design and patients
We recruited women undergoing primary breast cancer 
surgery or operative biopsy at Odense University Hospital 
in Denmark (1993–1998). Inclusion criteria were Danish 
citizenship and a postal address within the County of 
Funen for at least 1 year. Women with any previous 
cancer diagnosis were excluded. A fasting blood sample 
was drawn on the morning of surgery whenever possible 
(n, 154). For practical reasons, some patients contributed 
with a blood sample at least 1 month postoperatively 
(median 3 months) instead of preoperatively (n, 186). A 
few patients contributed with a blood sample on both 
occasions (n, 29). For each cancer patient, two healthy 
women of the same age and from the same geographical 
region were invited to serve as control subjects (n, 614). 
This matching was performed with the aid of the Danish 
Central Office of Civil Registration. A flow diagram deriv-
ing the cases and controls is shown in Fig. S1.
All breast cancer patients and control subjects partici-
pated in a research assessment visit, which included physical 
examination, anthropometric measures, and questionnaire. 
The latter was developed specifically for this cohort and 
included smoking habits, menopausal status, medication, 
medical history and body composition in the past. After 
surgery, tumors were described by size, histological type 
and grade [16], estrogen receptor status [17] and lymph 
node involvement. Each participant gave informed consent 
prior to inclusion, and the study was approved by the 
local ethics committee. The study was performed in accord-
ance with the 1975 declaration of Helsinki.
Outcome measures
Patients were followed for up to 10 years with regular 
clinical visits. Disease- free survival was recorded for each 
individual until the end of the clinical follow- up schedule. 
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All- cause mortality for patients with breast cancer was 
recorded until December 2010. All data was obtained from 
The Danish Breast Cancer Cooperative Group (DBCG), 
a Danish nationwide initiative comprising historical patient 
records on breast cancer disease, treatment, and outcome. 
All patients in this study were treated according to the 
DBCG 89 protocol (Fig. S2), a national guideline used 
to allocate patients with breast cancer to treatment from 
1990 to 2000 [18]. In brief, patients were divided into 
four distinct treatment groups according to menopausal 
status, tumor size, malignancy grade, steroid receptor status 
of the tumor and lymph node involvement. These were 
Protocol A, no adjuvant therapy; Protocol B, ovarian 
radiation or cyclophosphamide–methotrexat–fluorouracil 
(CMF) chemotherapy every third week for a total of nine 
times; Protocol C, tamoxifen with or without megestrol 
for varying durations; and Protocol D, CMF or cyclo-
phosphamide–epirubicin–fluorouracil (CEF) chemother-
apy every third week for a total of nine times, with or 
without pamidronate (Fig. S3). Patients were allocated to 
treatment independently of study participation.
Nottingham Prognostic Index
The Nottingham Prognostic Index (NPI) has been widely 
used by breast cancer clinicians across Europe since its 
early descriptions by Blamey in 1979 [19] and subsequent 
modifications. Importantly, for the purpose of the present 
analysis, it provides 10- year survival estimates contem-
poraneous with the treatment period of this study. NPI 
is calculated as: lymph node (LN) stage (1–3) + Grade 
(1–3) + maximum diameter (cm × 0.2), giving an observed 
range of NPI from 2.08 (LN negative, grade 1, 0.4 cm) 
to 6.8 (LN Stage 3, grade 3, size 4.9 cm). There are six 
NPI groups recognized by scores as: an excellent prog-
nostic group (EPG) with an observed NPI range of 2.00 
to ≤2.40, good (GPG) 2.41 to ≤3.40; moderate I (MPG 
I) 3.41 to ≤4.40, moderate II (MPG II) 4.41 to ≤5.40, 
poor (PPG) 5.41 to ≤6.40, and very poor (VPG) 6.41 
to 8.00. For this analysis, the PPG and VPG were com-
bined because of small sample sizes. The corresponding 
10- year survivals are 96%, 93%, 81%, 74%, 50%, and 
38% [20].
Serum assays
All methods are thoroughly described elsewhere [21]. In 
brief, we measured IGF bioactivity by our in- house KIRA 
assay, which is designed to measure the ability of a given 
sample to phosphorylate the IGF- IR in cultured cells in 
vitro under physiological conditions. The assay was per-
formed as originally described with modifications, please 
see [21]. As the IGF- IR can be activated by IGF- I, IGF- II, 
and pro- IGF- II, we nominated the output of the bioassay 
as bioactive IGF.
We used gel chromatography (FPLC) at low pH to 
separate IGF- I, IGF- II, and pro- IGF- II from the IGFBPs. 
This method is cumbersome, but nevertheless regarded 
as the gold standard for separating IGFs from IGFBPs 
[21]. After FPLC, IGF- I, IGF- II, and pro- IGF- II were 
determined by time- resolved immunofluorometric assays 
(TR- IFMAs) developed and validated in our laboratory 
[21]. IGFBP- 2 was measured by a TR- IFMA as previously 
described [21].
IGFBP- 3 was measured by a commercial kit (# IS- 4430) 
from IDS (Immunodiagnostic Systems Nordic A/S, 
Copenhagen, Denmark), using the automated iSYS platform 
[22]. The IGFBP- 3 kit was generously supplied by the 
manufacturer. PAPP- A was measured by a commercial 
kit from Ansh Labs (Webster, TX), generously provided 
by the manufacturer. Routine biochemical measurements 
were performed at the hospital’s laboratory using widely 
available automated assays. All samples were analyzed in 
a blinded fashion in random order.
Model developments
We developed conventional Cox prediction models to 
estimate associations and their 95% confidence intervals 
(CIs) for age and NPI (as a dummy variable) and IGF- 
related analytes (as continuous variables), and the survival 
endpoint of interest. Bootstrapping was used (1000 itera-
tions) to estimate 95% confidence intervals (CIs).
In addition to the conventional survival models, we 
investigated (nonlinear) solutions that do not rely on 
assumptions such as proportional hazards. Such approaches 
have shown comparable results with classical methods for 
clinical data, and improved performances for high- 
dimensional data, such as microarray [23]. To this end, 
we developed SANN and SSVM models. The SANN model 
utilized the commonly used feed- forward network structure 
consisting of three layers (input, hidden, and output). 
Here, the log hazard was modeled as a function of covari-
ates with a single linear output. The SSVM model utilized 
a Gaussian kernel function with cost and gamma param-
eters set at 0.1 (varying these parameters did not cause 
significant differences in the results).
Associations between the SANN and SSVM based scores 
and the real patient time to event was evaluated by the 
C- index (a measure of concordance between a predictive 
biomarker and censored survival outcome) [24], area under 
the curve (AUC) and hazard Ratio (HR) as calculated 
from Kaplan–Meier (KM) survival curves. The C- index 
assesses the concordance between the predicted and 
observed survival, with a value of 0.5 indicating random 
predictions, and 1 for perfect predicted survival. KM curves 
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were generated based on the model scores where patients 
were stratified into high and low risk according to the 
median prediction.
Model performance is often reported on the data used 
to fit the model, resulting in highly biased model esti-
mates. To avoid this common pitfall, cross- validated esti-
mates of survival distributions for predicted risk groups 
were computed as described by Simon [25]. Briefly, leave- 
one- out (LOO) cross- validation was used, where in each 
iteration one sample was left out of model fitting and a 
survival risk model was developed. Risk groups were defined 
based on the median risk score in this training set. The 
model was then applied to the left out sample resulting 
in a risk score and assignment to a risk group. This 
process was repeated for each of the training loops so 
that each sample was left out once and therefore had 
been classified as high or low risk using a model that 
they were not part of in any way. Model estimates were 
then computed by grouping all left out samples together 
and are therefore cross- validated and unbiased.
As IGF- related peptides were the biomarkers of interest, 
we first set a core model of non- IGF variables, namely 
age and NPI. We then added each of the following vari-
ables separately to the model: IGFBP- 2, PAPP- A, BMI, 
IGF- I, IGF- II, pro- IGF- II, and IGFBP- 3.
Statistical analyses
Baseline characteristics were compared by Kruskal–Wallis 
and chi- squared tests as appropriate.
For all models, receiver operating characteristic (ROC) 
curves were generated from postregression and post- 
training estimations where 95% confidence intervals were 
calculated from the bootstrapping process. Optimal sen-
sitivities and specificities were derived from the ROC 
curves. The primary summary performance indicator of 
“accuracy” was denoted by the AUC—values of 1.0 and 
0.5 being perfect and random discrimination, respectively. 
In addition to the training set estimations, the cross- 
validated estimates were also calculated as described in 
the methods.
Survival artificial neural networks and SSVM models 
were compared statistically using their respective C- indices 
by estimating the variance of each estimator and the 
covariance of the two estimators under comparison. A 
z- score test is then constructed to compare the two sets 
of predicted scores [26].
For the main performance model (postestimations of 
the Cox model), the discriminatory performance was 
assessed using two methods: (1) the Hanley and McNeil 
[27], a widely used method for comparing ROCs using 
between- area correlations assuming binomial distributions 
and comparing paired data; and (2) the method by Pencina 
et al. [28], which derives a net reclassification improve-
ment (NRI) output, an index of net change in events 
versus nonevents detected, which in turn focuses on medi-
cal decision making. We argue that, for most clinical 
settings, a NRI value of greater than 10%, over and above 
the conventional prognostic model, indicates a promising 
biomarker or set of biomarkers. The validity of the pro-
portional hazards assumption was tested using Schoenfeld 
residuals; no deviations from proportionality were identi-
fied. SANN and SSVM modeling used R (version 3.1.2, 
R Foundation for Statistical Computing, Vienna, Austria); 
other statistical analyses were carried out in STATA (ver-
sion 12.0, College Station, TX).
Results
Baseline characteristics
The baseline patient, tumor, and treatment characteristics 
according to tertiles of IGFBP- 2 and PAPP- A are shown 
in Table 1 for the 301 women (with complete NPI and 
IGF data) with early- breast cancer treated by surgery (with 
and without adjuvant therapies) at the Odense University 
Hospital, from 1993 to 1998. The median age was 55 years; 
median BMI was 24.9 kg/m2; 71% were postmenopausal; 
tumors were ER and PR positive in 76% and 38%, respec-
tively; 37% were node positive; median NPI was 3.3; 
approximately a half were surgically treated by mastectomy; 
and approximately a half had no adjuvant therapy.
Across the tertiles of circulating IGFBP- 2, there was 
an inverse association with BMI (P = 0.0001), but no 
significant associations with other factors. Across the tertiles 
of circulating PAPP- A, there were no significant associa-
tions with other factors.
IGFs: cancer versus controls
The distributions of circulating IGFs, bioactive IGF, 
IGFBP- 3, and PAPP- A, according to tertiles of IGFBP- 2 
and PAPP- A, for women with breast cancer versus controls 
(516 with complete IGF data), are shown in Table 2. For 
some of the measurements (i.e., total IGF- I, IGFBP- 3, 
and PAPP- A), we observed statistically significant but 
hardly biologically relevant differences between median 
values for women with cancer compared with well- matched 
controls, whereas the remaining measurements (i.e., 
IGFBP- 2, bioactive IGF, total IGF- II, and pro- IGF- II) did 
not differ between the two groups.
Across the tertiles of circulating IGFBP- 2, there was 
an inverse association with total IGF- II (P = 0.0004); an 
inverse association with IGFBP- 3 (P = 0.0001), and a 
positive association with PAPP- A (P = 0.0001). Across 
the tertiles of circulating PAPP- A, there was an inverse 
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Table 1. Baseline patient, tumor and treatment characteristics according to tertiles of IGFBP- 2 and PAPP- A, Odense University Hospital Breast Cancer 
series, 1993–1998.
Totals Tertile 1 Tertile 2 Tertile 3 Ptrends
IGFBP- 2
IGFBP- 2 μg/L 253 (170–358) 138 (114–167) 252 (224–281) 415 (358–488)
N 301 99 100 102
Median age (IQR) years 55 (50–62) 56 (50–63) 54 (50–61) 55 (48–63) 0.7321
Median BMI (IQR) kg/m2 24.9 (22.6–28.9) 27.9 (24.7–32.0) 24.7 (22.9–26.9) 22.8 (20.8–25.4) 0.00011
Menopausal status
Premenopausal 88 (29) 25 (25) 28 (28) 35 (34) 0.3492
Postmenopausal 213 (71) 74 (75) 72 (72) 67 (66)
Tumor grade
Grade 1 110 (36) 35 (35) 37 (37) 38 (37) 0.9452
Grade 2 144 (48) 49 (50) 49 (49) 46 (45)
Grade 3 47 (16) 15 (15) 14 (14) 18 (18)
Tumor ER status
Positive 201 (76) 72 (84) 66 (74) 63 (71) 0.1162
Negative 63 (24) 14 (16) 23 (26) 26 (29)
Unknown 37 13 11 13
Tumor PR status
Positive 98 (38) 28 (33) 35 (41) 35 (39) 0.5752
Negative 161 (62) 56 (67) 51 (59) 54 (61)
Unknown 42 15 14 13
Node status
Positive 111 (37) 36 (36) 39 (39) 36 (35) 0.8542
Negative 190 (63) 63 (64) 61 (61) 66 (65)
Median NPI score (IQR) 3.3 (2.8–4.4) 3.3 (3.1–4.4) 3.3 (2.8–4.4) 3.4 (2.5–4.4) 0.9801
Surgical treatment
Lumpectomy 155 (52) 54 (55) 57 (57) 44 (43) 0.1092
Mastectomy 146 (48) 45 (45) 43 (43) 58 (57)
Treatment protocol
No adjuvant therapy 160 (53) 50 (51) 53 (53) 57 (56) 0.2772
Ovarian ablation 35 (12) 7 (7) 14 (14) 14 (14)
Tamoxifen 59 (20) 27 (27) 17 (17) 15 (15)
Chemotherapy 47 (16) 15 (15) 16 (16) 16 (16)
PAPP- A
PAPP- A μg/L 0.82 (0.68–1.00) 0.63 (0.56–0.68) 0.81 (0.77–0.88) 1.10 (1.00–1.3)
N 301 99 100 102
Median age (IQR) years 55 (50–62) 54 (50–60) 57 (51–62) 56 (48–64) 0.2971
Median BMI (IQR) kg/m2 24.9 (22.6–28.9) 25.4 (22.9–29.7) 25.1 (22.8–29.1) 24.2 (22.0–27.1) 0.1911
Menopausal status
Premenopausal 88 (29) 31 (31) 20 (20) 37 (36) 0.0342
Postmenopausal 213 (71) 68 (69) 80 (80) 65 (64)
Tumor grade
Grade 1 110 (37) 38 (38) 34 (34) 38 (37) 0.8752
Grade 2 144 (48) 48 (48) 50 (50) 46 (45)
Grade 3 47 (16) 13 (13) 16 (16) 18 (18)
Tumor ER status
Positive 201 (76) 74 (82) 63 (72) 64 (74) 0.2262
Negative 63 (24) 16 (18) 25 (28) 22 (26)
Unknown 37 9 12 16
Tumor PR status
Positive 98 (38) 26 (30) 38 (44) 34 (40) 0.1222
Negative 161 (62) 62 (70) 48 (56) 51 (60)
Unknown 42 11 14 17
Node status
Positive 111 (37) 38 (38) 34 (34) 39 (38) 0.7662
Negative 190 (63) 61 (62) 66 (66) 63 (62)
Median NPI score (IQR) 3.3 (2.8–4.4) 3.3 (2.8–4.4) 3.3 (3.1–4.3) 3.4 (2.5–4.4) 0.7011
(Continues)
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association with total IGF- II (P = 0.0047) and pro- IGF- II 
(P = 0.0165). The correlations between the IGF- related 
peptides in women with breast cancer (Table S2) broadly 
mirrored those in women without cancer (Table S3).
Cox models: recurrence- free survival
With a median follow- up of 68 months, there were 105 
recurrent events (total RFS events were 120). The 5- and 
10- year RFS rates were 77 (95% CIs: 72–81) percent and 
55 (95% CIs: 48–61) percent, respectively. We screened vari-
ous patient and tumor- related factors, and all seven IGF- 
related peptides as potential prognosticators for RFS using 
Cox regression models. By univariate analyses (Table 3), the 
following were significant: age (P = 0.049); highest versus 
lowest NPI category (P = 0.006); IGFBP- 2 (P = 0.002); and 
PAPP- A (P < 0.001). We included these significant variables 
in the multivariate analysis—all remained significant, though 
generally with attenuation of effect size. By multivariate 
models, we additionally tested treatment- related factors—but 
these did not turn out significant (Table S4).
To illustrate the potential clinical utility of IGFBP- 2 
and PAPP- A as prognostic biomarkers, we constructed 
Kaplan–Meier curves for RFS according to tertiles of 
IGFBP- 2 and PAPP- A (Fig. 1). For IGFBP- 2, the dis-
crimination for 10- year RFS was modest—61%, 59%, 
Table 2. Distributions of circulating insulin- like growth factors (IGF), IGF- binding proteins, and PAPP- A, according to tertiles of IGFBP- 2 and PAPP- A, 
for women with breast cancer treated at Odense University Hospital, 1993–1998, and controls.
Controls 
(n = 516) Cancer (n = 301) 1Pversus controls
IGFBP- 2
1Pacross tertilesTertile 1 Tertile 2 Tertile 3
IGFBP- 2 μg/L 255 (176–366) 253 (170–358) 0.681 138 (114–167) 252 (224–281) 415 (358–488)
Total IGF- I μg/L 87 (65–110) 92 (70–113) 0.032 102 (71–129) 92 (74–112) 88 (68–104) 0.022
IGF bioactivity μg/L 1.19 (0.97–1.62) 1.15 (0.84–1.50) 0.141 1.34 (0.92–1.73) 1.25 (0.86–1.53) 0.98 (0.72–1.26) 0.009
Total IGF- II μg/L 572 (498–652) 585 (500–667) 0.276 621 (522–717) 596 (504–653) 540 (476–624) 0.0004
Pro- IGF- II μg/L 142 (112–175) 146 (112–178) 0.528 150 (114–193) 153 (117–182) 137 (108–167) 0.023
IGFBP- 3 μg/L 4000 (347–4505) 4113 (3578–4599) 0.044 4450 (4048–5009) 4173 (3585–4534) 3689 (3354–4231) 0.0001
PAPP- A μg/L 0.80 (0.64–0.96) 0.82 (0.68–1.00) 0.030 0.75 (0.64–0.91) 0.79 (0.67–0.95) 0.94 (0.74–1.14) 0.0001
PAPP- A
1Pacross tertilesTertile 1 Tertile 2 Tertile 3
PAPP- A μg/L 0.63 (0.56–0.68) 0.81 (0.77–0.88) 1.10 (1.00–1.3)
Total IGF- I μg/L 98 (74–119) 88 (70–114) 93 (68–108) 0.185
IGF bioactivity μg/L 1.15 (0.86–1.43) 1.20 (0.86–1.71) 1.10 (0.82–1.54) 0.794
Total IGF- II μg/L 611 (528–693) 594 (519–662) 536 (470–625) 0.0047
Pro- IGF- II μg/L 153 (120–192) 150 (113–178) 131 (104–168) 0.0165
IGFBP- 2 μg/L 231 (137–301) 226 (167–344) 323 (219–416) 0.0001
IGFBP- 3 μg/L 4167 (3647–4799) 4173 (3605–4648) 3937 (3492–4430) 0.063
1Kruskal–Wallis test.
Totals Tertile 1 Tertile 2 Tertile 3 Ptrends
Surgical treatment
Lumpectomy 155 (52) 46 (46) 57 (57) 52 (51) 0.3282
Mastectomy 146 (48) 53 (54) 43 (43) 50 (49)
Treatment protocol
No adjuvant therapy 160 (53) 54 (55) 56 (56) 50 (49) 0.6322
Ovarian ablation 35 (12) 10 (10) 9 (9) 16 (16)
Tamoxifen 59 (20) 21 (21) 21 (21) 17 (17)
Chemotherapy 47 (16) 14 (14) 14 (14) 19 (19)
BMI, body mass index; IQR, interquartile range; NPI, Nottingham Prognostic Index.
Values in parentheses are percentages unless otherwise stated. Total sum of percentages may not equal 100%.
1Kruskal–Wallis test.
2Chi- squared test for multiple comparisons.
Table 1. (Continued)
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and 46%, for the low, mid, and high tertile, respectively 
(P = 0.020). For PAPP- A, the discrimination for 10- 
year RFS was moderately better—67%, 57%, and 42%, 
for the low, mid, and high tertile, respectively 
(P = 0.004).
Second, to predict for RFS, we explored the performance 
characteristics of models including IGFBP- 2 and PAPP- A 
(Fig. 2). The core model (model 1) was exclusively based 
on clinically available parameters—age and NPI. For model 
1, the AUC was 0.626. We initially added IGFBP- 2 and 
Table 3. Univariate and multivariate modeling for circulating IGF- related peptides with recurrence- free survival1 as endpoint, Odense University 
Hospital Breast Cancer series, 1993–1998.
Incremental unit
Univariate Multivariate
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Age Per 10 years 1.258 1.001, 1.581 0.049 1.248 0.995, 1.567 0.055
BMI Per 5 kg/m2 0.865 0.718, 1.042 0.129
Menopausal status
Premenopausal 1.000 Referent
Postmenopausal 1.281 0.839, 1.955 0.252
Nottingham Prognostic Index
Category 1 2.00–2.402 1.000 Referent 1.000 Referent
Category 2 2.41–3.402 0.670 0.409, 1.097 0.112 0.768 0.466, 1.265 0.300
Category 3 3.41–4.402 0.789 0.446, 1.395 0.416 0.956 0.534, 1.711 0.880
Category 4 4.41–5.402 1.008 0.569, 1.784 0.977 1.163 0.651, 2.077 0.611
Category 5 5.41–8.002 2.383 1.288, 4.408 0.006 2.385 1.278, 4.451 0.006
IGF- related peptides3
Total IGF- I μg/L Per doubling 0.902 0.664, 1.227 0.515
IGF bioactivity μg/L Per doubling 0.754 0.494, 1.150 0.190
Total IGF- II μg/L Per doubling 1.054 0.598, 1.860 0.855
Pro- IGF- II μg/L Per doubling 0.801 0.582, 1.102 0.173
IGFBP- 2 μg/L Per doubling 1.474 1.160, 1.875 0.002 1.397 1.089, 1.793 0.008
IGFBP- 3 μg/L Per doubling 0.903 0.493, 1.654 0.742
PAPP- A μg/L Per doubling 1.952 1.364, 2.792 <0.001 1.595 1.114, 2.282 0.011
BMI, body mass index; CI, confidence intervals; NPI, Nottingham Prognostic Index.
All analyses were performed as Cox regression models.
1Events for recurrence- free survival were any recurrent disease or death, whichever came first.
2NPI scores range from 2.00 to 8.00.
3All IGF- related peptide distributions log- transformed to base 2.
Figure 1. The recurrence- free survival according to tertiles of IGFBP- 2 (left graph) and PAPP- A (right graph). Blue: upper tertile, red: midtertile, and 
green: upper tertile.
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PAPP- A, separately, with modest improvements in AUC 
compared with model 1 (model 2 vs. 1, P = 0.079; model 
3 vs. 1, P = 0.020). We then added IGFBP- 2 plus PAPP- A 
to the core model, yielding an AUC of 0.694 (model 4 
vs. 1, P = 0.012).
We tested additional models including BMI (as BMI 
was inversely associated with IGFBP- 2), but there was no 
material improvement in performance. We also tested 
models with six IGF- related peptides (excluding IGF bio-
activity because this measurement was only determined 
in a subgroup of patients) and again, and there was no 
material improvement in performance (Table S5).
We then explored an additional decision tool, namely 
the NRI in a model that included age, NPI, IGFBP- 2, 
and PAPP- A (the latter two log- transformed). We explored 
various combinations of cutoffs for the two IGF- related 
biomarkers at 40%, 50%, and 60% of the respective dis-
tributions. In the main, NRI values were equal to or less 
than the a priori 10% threshold, with one exception for 
cutoffs 40% and 50% for IGFBP- 2 and PAPP- A, respec-
tively, where the NRI was 14% (P = 0.042), however, 
with a wide standard error (Table S6). Accordingly, this 
result might have occurred by chance due to multiple 
testing.
Machine- Learning- driven models: 
recurrence- free survival
With RFS as the endpoint, we repeated the above per-
formance characteristics analyses using the SANN and 
SSVM models. We speculated that these machine- driven 
approaches might better capture the MDR of the IGF- 
related peptides [15]. The optimal models for SANN and 
SSVM, in the testing sets, yielded AUCs of 0.665 and 
0.690 for RFS as endpoint (Table 4)—in other words, 
there was no material improvement in performance over 
the Cox model.
Overall survival
From the 301 women, there were 107 deaths during 
follow- up. The 5- and 10- year OS rates were 90 (95% 
CIs: 87–93) percent and 79 (95% CIs: 74–83) percent, 
respectively. We repeated the same analyses as was per-
formed for RFS. Results were similar to those for RFS. 
After screening, again similar variables were significant 
or borderline significant by univariate analysis—namely 
age (P = 0.053); highest versus lowest NPI category 
(P < 0.001); IGFBP- 2 (P = 0.017); and PAPP- A (P = 0.001), 
Figure 2. Receiver operating characteristic (ROC) curves of model 1 (blue) and model 4 (red). The models and their AUCs are shown in the Table 
below the graph.
AUC (95% CIs) Comparison P 
value*
Model 1 (age, NPI category) 0.626 (0.561, 0.691)
Model 2 (age, NPI category, IGFBP-2) 0.667 (0.605, 0.729) Model 2 versus 1 0.079
Model 3 (age, NPI category, PAPP-A) 0.679 (0.618, 0.741) Model 3 versus 1 0.020
Model 4 (age, NPI category, IGFBP-2, 
PAPP-A)
0.694 (0.634, 0.754) Model 4 versus 1 0.012
AUC: area under the curve derived from the ROC models. CI: confidence intervals.
*Henley’s test
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and negatively with pro- IGF- II (P = 0.025). In the mul-
tivariate analysis, effects of these factors were generally 
attenuated, with significance remaining for age and highest 
NPI category (Table S7). As above, we explored the per-
formance characteristics of models, including IGFBP- 2 and 
PAPP- A, to predict for OS. The AUC for the core model 
(model 1: age and NPI) was 0.607, increasingly modestly 
to 0.677 with the addition of IGFBP- 2 and PAPP- A, com-
bined (Table 4). SANN and SSVM models added no 
additional performance enhancement for OS.
Additional analyses
Recurrence after initial treatment for breast cancer may 
occur after a long disease- free period—a biological process 
known as dormancy [29]. We tested whether or not cir-
culating IGF- peptides differentially impacted on recurrent 
disease events in the first five years versus those manifesting 
after 5 years, by repeating our recurrence- free analysis trun-
cated at 60 months. The previously observed associations 
were broadly unchanged, with the exception that PAPP- A 
was not significant in this model, whereas circulating IGFBP- 2 
remained an independently prognostic factor (Table S8).
We explored the influence of menopausal status in all 
our models; it was not a significant prognosticator (data 
not shown).
Discussion
Main findings
Among women with long- term follow- up after breast 
cancer treatment, increasing concentrations of circulating 
IGFBP- 2 and PAPP- A, determined at start of treatment, 
were independently associated with adverse prognosis; 
but when these biomarkers were tested against a clini-
cally used prognostic model, namely NPI, there was only 
a modest improvement in performance characteristics. 
We speculated that machine- driven approaches might 
enhance performance characteristics, by better capturing 
multidimensional relationships, but here too, improve-
ments beyond routinely used prognostic models were 
only modest. These findings illustrate an important prin-
ciple in biomarker qualification—measured circulating 
proteins, such as IGF- related proteins, may demonstrate 
independent prognostication, but this does not necessarily 
translate into substantial improvement in clinical 
performance.
Limitations and strengths
There are a number of potential limitations. First, the 
sample size was relatively small—we countered this by 
selecting RFS as the primary endpoint, which accumulated 
a large number of events over the long follow- up. Second, 
there was lack of external validation of the model on an 
independent dataset. To partly address this, we used an 
approach of running 100 iterations on randomly selected 
proportions of the data and demonstrated consistency of 
our results. Third, machine- learning methods identify data 
patterns by knowledge acquisition through an iterative 
learning process that allows development of nonlinear 
models and may intrinsically be disadvantaged by overfit-
ting and high variability in the imputed data. In this 
Table 4. Performance characteristics for models derived by Cox models, 
survival artificial neural networks (SANN), and survival support vector 
machines (SSVM), for recurrence- free survival and overall survival.
Training set Testing set
AUC (95% CIs) AUC (95% CIs)
Recurrence- free survival
Cox model
Model 1 (age, NPI 
category)
0.626 (0.561–0.691)
Model 4 (age, NPI 
category, IGFBP- 2, 
PAPP- A)
0.694 (0.634–0.754)
SANN
Model 1 (age, NPI 
category)
0.699 (0.697–0.702) 0.648 (0.645–0.652)
Model 4 (age, NPI 
category, IGFBP- 2, 
PAPP- A)
0.757 (0.754–0.759) 0.665 (0.661–0.669)
SSVM
Model 1 (age, NPI 
category)
0.611 (0.608–0.614) 0.606 (0.603–0.609)
Model 4 (age, NPI 
category, IGFBP- 2, 
PAPP- A)
0.690 (0.688–0.693) 0.690 (0.687–0.693)
Overall survival
Cox model
Model 1 (age, NPI 
category)
0.607 (0.543–0.670)
Model 4 (age, NPI 
category, IGFBP- 2, 
PAPP- A)
0.677 (0.616–0.738)
SANN
Model 1 (age, NPI 
category)
0.715 (0.712–0.718) 0.652 (0.648–0.656)
Model 4 (age, NPI 
category, IGFBP- 2, 
PAPP- A)
0.780 (0.778–0.782) 0.670 (0.666–0.674)
SSVM
Model 1 (age, NPI 
category)
0.631 (0.628–0.634) 0.634 (0.631–0.368)
Model 4 (age, NPI 
category, IGFBP- 2, 
PAPP- A)
0.721 (0.719–0.724) 0.725 (0.722–0.728)
IGFBP- 2, insulin- like growth factor- binding protein 2; NPI, Nottingham 
Prognostic Index; PAPP- A, pregnancy- associated plasma protein A.
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analysis, overfitting was minimized with appropriate regu-
larisation, early stopping, and robust cross- validation [30].
There are several strengths. First, we used a dataset of 
IGF- related peptides, which were validated in previous 
publications and consistent with the literature in terms 
of inter- relationships between IGFs and with age and BMI 
[9, 31–33]. Second, we used the gold method (acid chro-
matography) to separate IGFs from the IGFBPs and assayed 
serum IGF- I and IGF- II against WHO reference prepara-
tions as assay calibrators. This is likely to reduce the 
assay dependence of our results—a phenomenon that is 
well- recognized for in particular IGF- I measurements [34, 
35]. Third, we derived values for accuracy, sensitivity, 
and specificity, necessary for clinical decision making. 
Finally, we also derived an alternate decision tool—net 
reclassification improvement—and showed this to be 
modest.
Findings in the context of other studies
In relation to serum IGFBP- 2, the findings in this study 
confirm observations in other reports that baseline IGFBP- 2 
in patients with cancer is prognostic for poorer outcome 
in patients with cervical [36], pancreatic [37], and ovarian 
[11] cancer. Previous studies show that circulating IGFBP- 2 
levels in women with ovarian cancer correlate with tumour 
tissue IGFBP- 2 mRNA levels [38], and in patients with 
colorectal cancer undergoing resection, elevated presurgery 
concentrations return to normal after resection [9]. 
Furthermore, in ascites from women with ovarian cancer, 
IGFBP- 2 levels were higher and correlated positively with 
serum IGFBP- 2 [39]. Collectively, these studies suggest 
that circulating IGFBP- 2 levels partly reflect tumor secreted 
protein.
The findings for IGFBP- 2 and PAPP- A contrast with 
the remainder of studied IGF variables; that is, IGF- I, 
IGF- II, pro- IGF- II, bioactive IGF, and IGFBP- 3. The latter 
biomarkers have no impact on survival in univariate 
analyses. This might seem contradictory to a large volume 
of epidemiology linking circulating total IGF- I with 
increased risk of pre- and postmenopausal breast cancer, 
and circulating IGFBP- 3 and postmenopausal breast cancer 
[8]. However, in the postdiagnosis setting, several studies 
have investigated the relationship between circulating IGFs 
and breast cancer survival, with inconsistent findings. In 
110 postmenopausal women following breast cancer sur-
gery, Pasanisi et al. [40] reported higher IGF- I levels 
among women who developed recurrences compared with 
recurrence- free (mean follow- up: 5.5 years), but these 
differences were not statistically significant. In 600 women 
from the HEAL trial, where biomarkers were measured 
at 30 months postoperatively, Duggan et al. [41] reported 
significant associations between IGF- I, IGF- I to IGFBP- 3 
ratio (as an approximation of free IGF- I), and all- cause 
mortality. However, the number of events was small (42 
deaths). We found no association between total IGF- I 
and survival, and no association when we directly deter-
mined IGF bioactivity (albeit in a subpopulation of our 
total cohort). Similarly, Goodwin et al. [42] measured 
circulating IGF- I, IGF- II, and IGFBP- 3 at 4–12 weeks 
postoperatively in 512 women with early- stage breast cancer 
and found no association with survival.
Biological plausibility
In the present study, the Cox regression analyses identi-
fied serum PAPP- A and IGFBP- 2 as independent prog-
nostications of both RFS and OS. However, inclusion of 
IGFBP- 2 and PAPP- A only marginally increased the pre-
dictive value above that of the NPI. Furthermore, the 
baseline concentrations of IGFBP- 2 and PAPP- A were 
virtually similar when comparing patients with cancer and 
healthy controls. Thus, one could argue that the NPI is 
already embedding the prognostic impact of IGFBP- 2 and 
PAPP- A, explaining why neither PAPP- A nor IGFBP- 2 
had any major impact as prognosticators when added to 
the NPI. Obviously, the present study does not allow us 
to draw such conclusions, but we do believe it is possible 
to justify the idea that PAPP- A and IGFBP- 2 are involved 
in breast cancer. Many studies support that IGFBP- 2 
expression plays an oncogenic role in breast cancer [43]. 
IGFBP- 2 is consistently expressed in most breast cancer 
tissues and expression levels associate with the grade of 
malignancy [43]. Even though there may be no overall 
relation between IGFBP- 2 staining intensity and survival, 
the survival among patients with ER- negative/IGFBP- 2- 
positive breast cancer tissue was impaired [44]. 
Furthermore, we have previously shown that IGFBP- 2 in 
breast cancer cells was a marker of resistance to anti- 
estrogen therapy, whereas cell proliferation did not depend 
on IGFBP- 2 expression [45].
The association between IGFBP- 2 and breast cancer 
appears to be intimately linked to the tumor suppressor 
phosphatase and tensin homolog (PTEN), which interacts 
with IGFBP- 2 in an IGF- independent manner [43, 46]. 
During normal conditions, PTEN limits the activation of 
the PI3K/AKT/mTOR pathway, thereby serving as an 
anabolic brake on cell proliferation and survival [46]. 
During malignant transformation, inactivating mutations 
of PTEN are frequent events. The functional lack of PTEN 
may lead to unopposed proliferation and anti- apoptosis 
via the PI3K/AKT/mTOR pathway. Interestingly, when not 
occupied by IGF- II, IGFBP- 2 has been shown to suppress 
PTEN in breast cancer cells [47]. Thus, the association 
between an elevated serum (free) IGFBP- 2 concentration 
and a poorer prognosis is likely to reflect an increased 
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tumor synthesis of IGFBP- 2, a suppressed PTEN level, 
and consequently an unopposed tumor growth.
PAPP- A was the only other IGF- related protein that 
associated with RFS: an elevated level predicting a poorer 
prognosis. PAPP- A is an IGFBP- specific protease, having 
IGFBP- 2 as a substrate. Therefore, the current observation 
of a positive correlation between serum concentrations 
of IGFBP- 2 and PAPP- A may appear counterintuitive. 
However, one has to remember that the ability of PAPP- A 
to cleave IGFBP- 2 is IGF- dependent, and even following 
binding of IGF, PAPP- A cleavage of IGFBP- 2 is a relatively 
slow process compared to cleavage of its other substrates 
[48]. Indeed, we have recent data indicating that PAPP- A 
only affects IGFBP- 2 marginally. In pleural effusions, where 
PAPP- A is close to 50- fold elevated as compared to serum, 
the degradation of IGFBP- 2 remains similar to that in 
serum [49] and in serum from lung cancer patients the 
major part of IGFBP- 2 circulates in its free form (data 
in preparation). On the basis of our recent and present 
data, we speculate that in vivo, IGFBP- 2 is primarily 
unoccupied and hence not only protected against PAPP- A 
degradation but also able to suppress PTEN [46, 47]. 
Another issue that remains to be investigated is whether 
the relationship between PAPP- A and IGFBP- 2 serum 
concentrations is causal.
We noted that serum PAPP- A was independently prog-
nostic for RFS in the long- term (full) model but not in 
the 5- year right- truncated model, suggesting that PAPP- A 
might have less influence in early recurrent disease events, 
although sample sizes were too small to make definitive 
conclusions. However, as we found no previous reports 
evaluating the association between prognosis and serum 
PAPP- A in patients with breast cancer, we have no data 
for comparison. Nevertheless, our results are not surpris-
ing given the laboratory data—that (1) PAPP- A is fre-
quently overexpressed in tumors, including breast cancer 
[3]; and (2) in vivo, PAPP- A overexpressing SKOV3 clones 
(ovarian cancer) have accelerated tumor growth compared 
with mutant PAPP- A and controls [50]. Investigation of 
angiogenesis indicates that overexpression of PAPP- A favors 
development of mature tumor vasculature [50]. The poten-
tial role of PAPP- A in breast cancer recurrence is further 
supported, albeit indirectly, by studies of stanniocalcin- 2, 
which recently was discovered to inhibit the proteolytic 
activity of PAPP- A, and hence its ability to liberate IGF- I 
[51]. Thus, in a study of primary breast cancer tumors, 
Joensuu et al. found a higher expression level of stanni-
ocalcin- 2 in tumors which showed a very late relapse. As 
the relationship between PAPP- A and stanniocalcin- 2 was 
not known at that time point, the authors suggested that 
stanniocalcin- 2 acted as a survival factor for breast cancer 
cells [52]. However, knowing that stanniocalcin- 2 inhibits 
the enzymatic function of PAPP- A, one may argue that 
by obstructing PAPP- A, stanniocalcin- 2 was indeed delay-
ing the recurrence of breast cancer rather than serving 
as a survival factor. Thus, even though PAPP- A in the 
present study was unable to serve as an additional prog-
nosticator of breast cancer recurrence, we believe it may 
still play a pathogenic role.
Implications and future studies
The parallel development of biomarker(s) and novel anti-
cancer therapies involves several stages—including discov-
ery, qualification, and validation—as outlined, for example 
by the Cancer Research UK biomarker roadmap (http://
www.cancerresearchuk.org/prod_consump/groups/cr_com 
mon/@fre/@fun/documents/generalcontent/cr_027486.pdf). 
As part of qualification, the sensitivity, specificity, and 
accuracy of a biomarker assay are compared with estab-
lished thresholds for minimally acceptable clinical perfor-
mance criteria. It is likely that single circulating biomarkers 
may not be sufficiently informative alone, whereas multiple 
biomarkers in combination with additional types of bio-
markers (e.g., imaging modalities) may yield clinically 
relevant information. This study shows that despite initial 
promise from the prognostic modeling, serum IGFBP- 2 
and PAPP- A fell short of steep changes in clinical per-
formance. If serum IGFBP- 2 and PAPP- A were to be 
pursued as clinical biomarkers, alternative studies might 
be to look at repeated measures and whether or not 
changes in values were prognostic. Equally, it is important 
to make decisions when to proceed no further with devel-
opment of some biomarkers.
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